Phase II
A COVID-19 vaccine candidate developed by Chinese pharmaceutical company Sinopharm triggered antibody-based immune responses in early and mid-stage trials.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 14, 2020.
A recent report in the New England Journal of Medicine reveals that the racial and ethnic minority groups most negatively-impacted by COVID-19 are also the least represented in these clinical studies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 10, 2020.
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 7, 2020.
Denmark-based Lundbeck discontinued a mid-stage proof of concept study of a schizophrenia drug following an interim analysis of data that indicated the study will not achieve statistical significance in its primary endpoint.
Several polls have suggested that as much as half of the U.S. population is unlikely to get the vaccine for a variety of reasons, including not feeling it is safe.
According to a warning from federal officials last week, dozens of drug companies, universities and medical device manufacturers owe more than a decade’s worth of data from clinical trials.
PRESS RELEASES